about
Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimensThe airway microbiome in cystic fibrosis and implications for treatment.Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis.Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methodsCholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients.Sputum induction improves detection of pathogens in children with cystic fibrosis.Molecular Identification of Staphylococcus aureus in Airway Samples from Children with Cystic Fibrosis.Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis.Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosisCystic fibrosis: a model system for precision medicine.Advances in the diagnosis and treatment of cystic fibrosis.Highlights from the 2016 North American Cystic Fibrosis Conference.Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?Cystic fibrosis transmembrane conductance regulator and pseudomonas.Microbes in bronchiectasis: the forest or the trees?Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.Narrowing in on early cystic fibrosis lung disease.Highlights from the 2015 North American Cystic Fibrosis Conference.Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects.Newborn screening for cystic fibrosisUnraveling the CFTR Function-Phenotype Connection for Precision Treatment in Cystic FibrosisHighlights from the 2017 North American Cystic Fibrosis ConferenceChanges in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D MutationBacterial Community Variability: Outliers May Be Leading Us AstrayChallenging scenarios in nontuberculous mycobacterial infection in cystic fibrosisHighlights from the 2018 North American cystic fibrosis conferenceNanodiagnostics to monitor biofilm oxygen metabolism for antibiotic susceptibility testing
P50
Q33770039-0F71BC0A-5FE7-4A41-BEE0-8BA1C3C1F85EQ33873287-DE672C2F-3FFF-4D74-80FB-FBA71BD4750BQ35058280-6BE6B4F8-C44D-4EEE-8889-CFE4547FC440Q35127881-82FC3818-69D1-4999-A9FF-787C045591B9Q35546970-4E7420EF-6350-484C-A152-811C7023BDE4Q35828811-04C71E92-4CD5-4049-99C4-D243597F3B52Q35903821-BB9E6DFB-78F5-4A3E-A9B6-A6DFEDE3BFBFQ36216240-3BE70FA9-6D4E-42FC-AEC3-DD3E77813E3CQ36488777-43DE167D-1FD8-434D-8C04-57488AC99472Q37097931-70151A75-18A4-4FD4-953C-18D153D573F2Q38231006-EB454E64-6813-442B-B351-DAD32CCEA843Q38684319-AD9DAA1A-9D42-4730-88B7-2013CE03F770Q42429426-4783A412-E16D-4B53-B7DE-7E0A55C6886FQ42992335-62E1505E-259C-4B43-9EE1-2352ACCED8A0Q43774755-03E41CE6-E23A-4F31-9B97-7DE036BFBC48Q44272126-0ED7B26B-AFC0-4DCF-A528-0EA62648370FQ44790185-344C2206-7E87-44D0-9E8F-01EAB90D02DDQ45294315-E138C30E-717E-4037-A49D-3EDA8343EA36Q46587344-A11D65A9-9042-4057-9F14-9756892D6759Q56430901-78336D0D-4F18-48E0-9B61-85B7F5BC9C2BQ64072700-AA420091-90AC-4F12-B6BC-3E12E3C72796Q88373814-3E165217-96F7-44C0-B4C2-70880B6B1CB5Q90656732-3C083F74-40ED-4B12-86D9-16F27ADA2ACDQ91485763-EB02811A-4658-443E-949F-83B77605181EQ91846221-E602ECD2-1E01-4C4A-A94A-B9DCCD97A144Q92037575-60E2B0A0-FBC6-43F0-B883-A9BC50CFA8B1Q93273551-7581E2A0-A79B-4F4C-B97C-C9C6F799ECEC
P50
description
researcher ORCID ID = 0000-0002-7507-9337
@en
wetenschapper
@nl
name
Edith T Zemanick
@ast
Edith T Zemanick
@en
Edith T Zemanick
@nl
type
label
Edith T Zemanick
@ast
Edith T Zemanick
@en
Edith T Zemanick
@nl
prefLabel
Edith T Zemanick
@ast
Edith T Zemanick
@en
Edith T Zemanick
@nl
P31
P496
0000-0002-7507-9337